Abstract. Cell migration and invasion are critical events during the progression to metastasis. Matrix metalloproteinase-1 (MMP-1) is involved in the progression of human malignancies, but the precise role of MMP-1 in tumor invasion and metastasis remains unclear. In the present study, we investigated the role of MMP-1 in tumor cell invasion and metastasis by overexpressing MMP-1 in prostate cancer cells. Overexpression of MMP-1 in prostate cancer cells increases cell invasion and migration as measured by modified transwell assays. Furthermore, the results from a bioluminescence tumor/metastasis model showed that the overexpression of MMP-1 significantly induces prostate tumor growth and the incidence of lung metastasis. We observed that this increase in tumor growth correlates with an increase in tumor angiogenesis. In addition, we assessed the importance of MMP-1 expression in cell invasion and migration by inhibiting MMP-1 activity with specific inhibitor and antibodies. Blockade of MMP-1 activity inhibited prostate cancer cell migration and invasion in vitro. Treatment of mice with an MMP-1 specific inhibitor significantly decreased prostate tumor growth and incidence of lung metastasis in vivo. Collectively, our findings suggest that MMP-1 plays an important role in prostate cancer progression during the invasive and metastatic stages of the disease.
Introduction
Approximately 27,050 prostate cancer-related deaths are predicted for this year alone in the United States. Despite recent improvements in diagnostic and therapeutic techniques, the survival rate of prostate cancer patients remains poor due to post-treatment recurrence of disease (1, 2) . The lack of effective therapies for advanced prostate cancer is related to a large extent to a poor understanding of the molecular changes underlying the progression of the disease toward invasion and metastasis (3) . Thus, the identification of new predictive biomarkers, which can serve as targets for more effective therapeutic and chemopreventative interventions, will improve clinical management of prostate cancer.
Tumor metastasis occurs by a series of steps including vessel formation, cell attachment, invasion and cell migration. As such, the regulation of metastasis is extremely complicated (4, 5) . Degradation of basement membranes and the stromal extracellular matrix are crucial steps for tumor invasion and metastasis. Matrix metalloproteinases (MMPs) comprise a family of human zinc-dependent endopeptidases responsible for degradation of the extracellular matrix (6, 7) . Among the MMPs, the collagenase MMP-1 has been identified as one of the most highly upregulated proteins in a variety of cancers, including colorectal, esophageal, pancreatic, gastric, breast, and malignant melanoma (8) (9) (10) (11) (12) (13) . Furthermore, elevated MMP-1 expression in atypical ductal hyperplastic tissues may serve as a marker for predicting which patients will develop invasive breast cancer (14) . However, there are no reports yet on its relationship with prostate cancer metastasis.
The present study was designed to examine the effect of MMP-1 overexpression on cell migration, invasion, angiogenesis and metastasis. We found that overexpressing MMP-1 in human prostate cancer cells promotes primary tumor growth and leads to increased lung metastases. Furthermore, blocking MMP-1 expression inhibits tumor cell migration, invasion, angiogenesis and metastasis. These findings indicate that MMP-1 is a novel target for therapeutic applications in prostate cancer.
Materials and methods
Cell culture and transfection conditions. The prostate cancer cell lines RWPE2, LNCaP, DU145 and PC3 were obtained from the American Type Culture Collection (Manassas, VA). LNCaP cells were cultured in RPMI medium supplemented with 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate (Invitrogen, Carlsbad, CA). PC3 and DU145 cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/ F12K (1:1). Both media contained 10% fetal bovine serum (Gibco BRL, Lewisville, TX) and 5% penicillin/streptomycin. RWPE2 cells were grown in K-SFM containing 50 μg/ml bovine pituitary extract, 5 ng/ml epidermal growth factor, and 1% penicillin/streptomycin solution. All cells were cultured in a 37˚C incubator with a 5% CO 2 humidified atmosphere. The MMP-1 expression vector (pCMV-neo/MMP-1) was prepared by inserting full-length human MMP-1 cDNA into a pCMV-neo vector (OriGene, Rockville, MD). The MMP-1 expression vector and empty vector-transfected cells were selected by growth in the presence of G418 (500 μg/ml), and then analyzed for MMP-1 expression using RT-PCR and immunoblotting.
Collagen zymography. Confluent prostate cells were maintained in serum-free media for 24 h. Equal amounts of conditioned media were loaded onto 10% polyacrylamide gels containing 1 mg/ml of collagen (Sigma, St. Louis, MO). After electrophoresis, the gels were washed and stained as described previously (15) . The substrate-degrading enzyme MMP-1 was identified as clear bands in the blue background.
Invasion and cell migration assay. We used 6.5-mm diameter Transwell inserts (Costar, Cambridge, MA) with the 8-μm pore membranes coated with Matrigel (Becton-Dickinson, Bedford, MA) to assess the invasive potentials of prostate cancer cells. Depletion of MMPs with antibodies and inhibitor was carried out as described previously (16) . Cells were detached, washed twice in PBS and resuspended in serum-free DMEM. A total of 5x10 4 cells in 0.2 ml were placed in each chamber as described (17) . After a 24-h incubation period, the cells in the upper chamber that did not migrate were gently scraped away and adherent cells present on the lower surface of the insert were stained with Hema-3 and photographed. For assessing cell migration, the assay was carried out essentially as above, except that the cells were plated on top of uncoated transwell inserts and incubated for 8 h.
In vitro angiogenesis assay. The endothelial tube-like formation assay was performed as described previously (6) . Human dermal endothelial cells (HDECs) were seeded on 8-well chamber slides at 4x10 4 cells per well. After cells adhered to the well (12 h), growth medium was replaced by conditioned medium. The conditioned media were collected from PC3 prostate cell cultures, which were pretreated with MMP-1 or VEGF neutralized antibodies at the indicated concentrations for 2 h at 37˚C before being added to HDEC. After a 48-h culture in the treated media, dead floating cells were washed away. To assess tube formation, the attached living cells were stained with anti-vWF (Dako, Carpenteria, CA). We quantified tube formation by measuring the number of branch points and the total number of branches per point in triplicate wells.
Dorsal skin-fold chamber model. Tumor angiogenesis was quantified in vivo using the transparent dorsal skin-fold chamber model (18) . Briefly, after total body anesthesia with ketamine (50 mg/kg) and xylazine (10 mg/kg), a dorsal air sac was made in the mouse by injecting 10 ml of air. After dorsal skin-fold preparation, chambers were inoculated with 2x10 6 prostate cancer cells. Ten days later, the animals were anesthetized and sacrificed. The animals were carefully skinned around the implanted chambers, and the implanted chambers were removed from the subcutaneous air fascia. The skin fold covering the chambers was photographed under visible light. The number of blood vessels within the chamber in the area of the air sac fascia was counted, and their lengths were measured.
Reverse transcription-PCR analysis. Cellular RNA was isolated using the Qiagen RNeasy kit and 1 μg of RNA was DNase-treated (10 U/μg of RNA, 1 h) and used as a template for the reverse transcription reaction (RT, 20 μl). RT reaction mix (Invitrogen) contained 1 μl (10 pm) of primers. The resultant cDNA was then used in PCR reactions and analyzed by gel electrophoresis. The following primers were used: MMP-1sense, 5'-CGA CTC TAG AAA CAC AAG AGC AAG A-3', and MMP-1 antisense, 5'-AAG GTT AGC TTA CTG TCA CAC GCT T-3'; GAPDH-sense, 5'-CGG AGT CAA CGG ATT TGG TCG TAT-3', and GAPDH-antisense, 5'-AGC CTT CTC CAT GGT GGT GAA GAC-3'. The PCR conditions were as follows: 95˚C for 5 min, followed by 40 cycles at 95˚C for 1 min, 58˚C for 1 min and 72˚C for 1 min. The final extension was at 72˚C for 5 min.
Immunoblot analysis. Cells were lysed in RIPA buffer and proteins quantified using a BCA assay (Pierce, Rockford, IL). Equal amounts of proteins in the samples were separated on SDS-PAGE gels. Membranes were probed with antibodies against MMP-1 (Biomeda, Foster City, CA) and GAPDH (Abcam, Cambridge, MA). Horseradish peroxidase-conjugated secondary antibodies (Biomeda, Foster City, CA) were used for detection of immunoreactive proteins by chemiluminescence (Amersham Biosciences, Piscataway, NJ).
Orthotopic mouse prostate tumor/metastasis model. Athymic male nude mice (nu/nu; 6-8 weeks old) were obtained from Harlan Sprague-Dawley (Indianapolis, IN). Animal handling and experimental procedures were approved by the University of Illinois College of Medicine Institutional Animal Care and Use Committee. Orthotopic implantation was carried out as described previously with minor modifications (19) . Briefly, after total body anesthesia with ketamine (50 mg/kg) and xylazine (10 mg/kg), a small incision was made to reveal the prostate gland. LNCaP cells stably expressing either empty vector or MMP-1 expression vector with luciferase reporter were injected into mouse prostate (10 6 cells per mouse). Prostate tumor growth and subsequent metastasis to lungs were assessed weekly using the in vivo imaging system coupled to Living Image acquisition and analysis software (Xenogen, Alameda, CA) according to the manufacturer's instructions. For inhibitor studies, 10 6 PC3-luc cells in PBS were injected into the mouse prostate. MMP-1 inhibitor (FN-439; Calbiochem, San Diego, CA) was injected intraperitoneally at a dose of 5 mg/kg twice a week for a maximum of 6 weeks. All mice were sacrificed at either 6 weeks postimplantation or when clinical conditions dictated euthanasia. We then excised, measured and weighed the prostate tumors. Part of the tumor was snap-frozen for RT-PCR analysis, and the remaining portion was placed in phosphate-buffered formalin and then ethanol before preparing paraffin sections for hematoxylin and eosin staining.
Histological analysis and immunohistologic staining. Tissues were fixed with formalin, embedded in paraffin, sectioned (5 μm) and stained with hematoxylin and eosin. Immunostaining was performed according to standard techniques using a polyclonal antibody specific for human vWF (Dako). Visualization of antibody binding was performed by the second antibody tagged with HRP following reaction to DAB (Sigma). Microvessel density was determined as described previously (17) .
Statistical analysis. Statistical comparisons were performed using ANOVA for analysis of significance between different values using GraphPad Prism software (San Diego, CA). Values are expressed as mean ± SD from at least 3 separate experiments and differences were considered significant at a p<0.05.
Results

Overexpression of MMP-1 enhances invasiveness and cell migration of prostate cancer cells.
To study the possible role of MMP-1 expression in the invasion and migration of prostate cancer cells, we generated MMP-1-overexpressing cells. We initially examined MMP-1 mRNA and protein levels in the prostate cancer cell lines RWPE2, LNCaP, DU145 and PC3. Among the four cell lines, only DU145 and PC3 cells highly expressed MMP-1 at both the mRNA and protein levels (Fig. 1a) . LNCaP, an MMP-1 null prostate cancer cell line that has a very low invasion index (19) , was transfected with either an MMP-1 expression vector or an empty vector. We observed high expression of MMP-1 in MMP-1-transfected cells but not in parental (mock) or empty vector-transfected cells as detected by RT-PCR and immunoblotting (Fig. 1b) . Differences in invasion between MMP-1-expressing cells and control LNCaP cells were evaluated using a Matrigel invasion assay. The results show that MMP-1 stably expressing LNCaP cells were significantly more invasive than the empty vector controls (Fig. 1c, left) . In addition, the rate of cell migration between these cells was also compared using the two-chamber assay with uncoated inserts (instead of Matrigel-coated filters). Interestingly, LNCaP cells stably expressing MMP-1 showed increased migration when compared with the empty vector controls (Fig. 1c, right) . Representative pictures are shown in Fig. 1d . Furthermore, to extend these findings to an additional prostate cancer cell line, RWPE2 cells were stably transfected with the MMP-1 expression vector and tested for invasion and migration. Similar to the results described above, RWPE2 cells stably expressing MMP-1 exhibited increased invasion and migration when compared with RWPE2 cells that did not express MMP-1 (data not shown).
MMP-1 overexpression promotes tumor growth and metastasis
in nude mice. We tested whether the invasive phenotype conferred by MMP-1 in LNCaP cells under in vitro conditions could be extended to an in vivo tumor model system. To produce orthotopic tumors in nude mice, LNCaP cells stably expressing either empty vector (control) or MMP-1 expression vector with luciferase reporter were injected into the prostate of immunodeficient mice. Tumor progression was monitored in mice using the Xenogen in vivo imaging system. We obtained photon counts from the tumor region on days 10, 20 and 40 (Fig. 2a, right) . The mice injected with LNCaP cells stably transfected with MMP-1 developed larger prostate tumors by day 40 when compared with the mice inoculated with cells transfected with the empty vector (Fig. 2a, left) . The presence of significant growth differences in prostate tumors between control and mice injected with MMP-1-overexpressing cells were confirmed by autopsy after imaging (data not shown). To determine the effect of MMP-1 on tumor metastasis, we dissected the lungs from each mouse and photon counts were recorded. The lungs derived from control mice injected with empty vectortransfected cells had low photon counts. In contrast, we observed a marked induction (3.7-fold) in the incidence of lung metastasis when primary tumor cells stably transfected with MMP-1 were seeded in host mice (Fig. 2b and c) . RT-PCR analysis confirmed expression of MMP-1 in prostate tumors developed from the LNCaP cells stably expressing MMP-1 (Fig. 2d) . These results clearly show that expression of MMP-1 in LNCaP prostate cancer cells significantly enhances both primary tumor growth and the in vivo incidence of lung metastasis.
Effect of MMP-1 overexpression on angiogenesis in vivo.
We investigated whether the accelerated tumor growth and metastasis that we observed could be due to tumor angiogenesis stimulated by MMP-1. Immunohistochemical staining for endothelial cells revealed much higher vWF-positive vascular structures within the prostate tumors developed from MMP-1-overexpressing cells than the empty vector controls (Fig. 3a) . Next, we used a dorsal skin-fold chamber model to further characterize the effects of MMP-1 overexpression on tumor angiogenesis in vivo. Although the implantation of a chamber containing cells transfected with empty vector did not promote tiny new vascular sprouts and branches similar to those that grew from pre-existing microvessels, there was a significant increase in angiogenic response in the skin-folds of mice implanted with chambers containing MMP-1-overexpressing cells (Fig. 3b) . Representative pictures are shown in Fig. 3c . These results suggest that enhanced MMP-1 expression increased angiogenic activity in prostate tumors.
MMP-1 depletion reduces invasion and migration of prostate cancer cells.
To further confirm the role of MMP-1 overexpression on the invasive properties of prostate cancer cells, we tested the effect of selective pharmacologic inhibition of MMP-1 on cell invasion and migration. We carried out inhibition studies using the well-characterized MMP-1 inhibitor FN-439 (16, 20, 21) . Our results showed the MMP-1 inhibitor induced a dose-dependent regulation on invasion; cells treated with the MMP-1 inhibitor at low doses of 1-100 nM showed no significant differences in invasion, whereas a higher dose of MMP-1 inhibitor (10 μM) significantly diminished the invasive potential of metastatic DU145 and PC3 cells (Fig. 4a) . We also assessed in vitro migration in response to the MMP-1 inhibitor using a Transwell migration assay. MMP-1 inhibitor suppressed the migration of DU145 and PC3 cells through uncoated, porous filters in a dose-dependent manner, with no significant effect at a concentration of 1-100 nM and a maximal effect at 10 μM (Fig. 4b) . Collagen zymography showed that 10 μM of MMP-1 inhibitor treatment significantly reduced MMP-1 activity in DU145 and PC3 cells (Fig. 4c) . In addition, we immunodepleted individual MMPs from DU145 and PC3 conditioned medium with the corresponding anti-human MMP antibodies. As shown in Fig. 4d , immunodepletion of MMP-1 from DU145 and PC3 conditioned medium caused a significant drop in cell invasion (left) and migration (right). Treatment of the DU145 and PC3 conditioned medium with antibodies directed against MMP-2 resulted in a slight drop in cell invasion and migration. However, simultaneous immunodepletion of MMP-1 and MMP-2 caused the same drop in invasion and migration as immunodepletion of MMP-1 alone. No effects were observed upon treatment with anti-MMP-3, -7 or -9 antibodies. Together, these data demonstrate that MMP-1 is capable of inducing invasion and migration in prostate cancer cells.
MMP-1 inhibitor suppresses in vitro and in vivo angiogenesis
of prostate cancer cells. Because tumor angiogenesis involves multiple factors, including endothelial cells (ECs) and tumor cells, we first tested whether PC3 cells exerted a pro-angiogenic effect on neighboring ECs through MMP-1 and other angiogenic proteins. We used the EC tube-like network formation assay, an in vitro assay that correlates well with in vivo angiogenic activity (22, 23) . EC networks increased 5.1-fold following exposure to PC3 conditioned media compared to basal media. Further, blocking antibodies to both MMP-1 and VEGF were able to abolish the angiogenic effects of the PC3 conditioned media on EC network formation (Fig. 5a) . However, because MMP-1 depletion alone resulted in a strong inhibition of network formation, we could not demonstrate an additive or synergistic effect of MMP-1 and VEGF inhibition. These data demonstrate the ability of MMP-1 to induce EC network formation. Notably, we found that conditioned media from PC3 cells treated with 10 μM of MMP-1 inhibitor suppressed tube formation (Fig. 5b) . Representative pictures are shown in Fig. 5c . We next used a dorsal skin-fold chamber model to further characterize the effects of MMP-1 inhibitor on tumor angiogenesis in vivo. Control experiments containing untreated PC3 cells did not interfere with neovascularization as shown by the formation of new vessels from the preexisting vasculature. In contrast, we observed significantly less angiogenic response in the skin-folds of mice implanted with chambers containing MMP-1 inhibitor-treated PC3 cells (Fig. 5d) . These data suggest that MMP-1 inhibitor suppressed angiogenesis both in vitro and in vivo.
Pharmacological inhibition of MMP-1 reduces tumor growth and metastasis in nude mice.
Having shown that the MMP-1 inhibitor affects prostate cancer cell invasion and angiogenesis, we investigated the effects of pharmacologic blockade of MMP-1 on the growth of PC3 orthotopic tumors in nude mice. We injected 1x10 6 PC3 cells stably expressing luciferase into the prostate of immunodeficient mice. Starting on day 6 after injection, mice were treated with either vehicle control or MMP-1 inhibitor (5 mg/kg intraperitoneally twice a week for a maximum of 6 weeks). Tumor progression was monitored in mice using the Xenogen in vivo imaging system. We obtained photon counts from the tumor region on days 10, 20 and 40 (Fig. 6a, right) . The tumors rapidly grew in control mice, resulting high photon counts in all control mice by day 40. In contrast, mice receiving the MMP-1 inhibitor developed prostate tumors of significantly smaller volume by day 40 (Fig. 6a, left) . We also assessed the efficacy of drug treatments as interventions during the natural formation of lung metastasis from prostate tumors. Although the lungs derived from control mice had high photon counts, there was a significant decrease in lung metastases in the MMP-1 inhibitor-treated mice (Fig. 6b) . RT-PCR analysis confirmed MMP-1 inhibition in prostate tumors developed from mice treated with the MMP-1 inhibitor (Fig. 6c) . Immunohistochemical staining for endothelial cells revealed prominent vWF-positive vascular structures within the tumor mass of the control groups. In contrast, significantly less vascularity was present in tumors developed from mice treated with the MMP-1 inhibitor (Fig. 6d) . These results suggest that MMP-1 can promote tumor growth, angiogenesis and metastasis, but significant inhibition of these processes can be achieved by inhibition of MMP-1.
Discussion
We investigated the potential implication of the MMP-1 in prostate cancer progression. This study provides the first direct evidence for a pivotal role of MMP-1 in primary prostate cancer growth, leading to metastatic dissemination. Several lines of evidence support these conclusions. First, MMP-1 is only expressed in the highly invasive prostate cancer cell lines DU145 and PC3. Second, the overexpression of MMP-1 in LNCaP prostate cancer cells, which have a low spontaneous metastasis rate, can promote in vitro tumor cell invasion as well as significantly enhance in vivo primary tumor growth and spontaneous metastatic potential. Third, overexpression of MMP-1 in LNCaP cells results in an enhancement of tumor angiogenesis. Fourth, blocking MMP-1 expression in PC3 prostate cancer cells significantly inhibited prostate tumor growth and the incidence of lung metastasis.
The regulation of cell invasion and migration is critical to the progression of cancer. Our studies show that MMP-1 overexpression enhances both the invasion and migration of human prostate cancer cells in vitro (Fig. 1) . In addition, we show that overexpression of MMP-1 is sufficient to promote growth and invasion of prostate cancer cells in an orthotopic tumor model (Fig. 2) . This orthotopic prostate tumor model seems clinically relevant because its tumor progressioncontaining metastasis mimics the clinical scenario. Our findings are in agreement with previous observations in colorectal carcinoma and breast cancer where overexpression of MMP-1 had a suggested potential role in cancer promotion (11, 14) .
Another interesting finding of our study was that overexpression of MMP-1 significantly induced tumor angiogenesis in vivo (Fig. 3) . Parts of the biological characteristics of tumor cells are closely associated with those of microvascular endothelial cells in tumor tissues (24) . Endothelial cell secretion of MMP-1 has been shown to assist angiogenesis in vivo (25) , and it follows that tumor cell production of MMP-1 should facilitate blood vessel growth in the tumor microenvironment. In addition, several investigators have reported that MMP-1 could stimulate endothelial cell growth (20, 26) . Furthermore, Goerge et al (20) reported that tumorderived MMP-1 is crucial for angiogenesis. Our results provide support to these findings.
There is now substantial evidence that the family of MMPs is important for various aspects of prostate tumorigenesis. Functionally, inhibitors of metalloproteinase activity attenuate the growth and invasion of tumors cells implanted into the flank (27) or prostate of rats (28, 29) . Our study also examined the specific effect of pharmacologic inhibition of MMP-1 on prostate tumor cell invasion, angiogenesis and metastasis (Figs. 4, 5 and 6 ). Although it could be speculated that tetrapeptidyl hydroxamic acid (FN-439) is not specific for MMP-1, it was shown previously that MMP inhibitor FN-439 targets MMP-1 but not MMP-2 or MMP-3 (20) . Consistent with this notion, we found that FN-439 significantly reduced MMP-1 activity (Fig. 4c) , but had no effect on MMP-9 or MMP-2 in DU145 and PC3 cells (data not shown). In addition, DU145 and PC3 cells had undetectable levels of MMP-3, MMP-7 and MMP-8 (data not shown). Taken together, these data strengthen our notion that MMP-1 plays an important role during the progression of human prostate cancer.
In conclusion, our studies have revealed the critical role of MMP-1 in invasion and tumor growth in the metastatic process. These findings provide new and important information on the progression of prostate cancer. The finding that MMP-1 influences metastatic potential, as shown in this study, raises the possibility that MMP-1 could be used as a molecular target in the anti-metastatic therapy of patients with prostate cancer.
